Effective treatments are lacking for idiopathic intracranial hypertension (IIH), a condition characterised by raised intracranial pressure (ICP) and papilloedema, and found almost exclusively in obese women. Weight loss and lowering body mass index (BMI) has been shown to lower ICP and improve symptoms in IIH; however, weight loss is typically not maintained meaning IIH symptoms return. The IIH:WT trial will assess whether bariatric surgery is an effective long term treatment for IIH patients with a BMI over 35 kg/m 2 . The National Institute for Health and Care Excellence (NICE) recommends bariatric surgery in people with a BMI over 35 kg/m 2 and a qualifying co-morbidity; currently IIH does not qualify as a co-morbidity.
INTRODUCTION Idiopathic Intracranial Hypertension
IIH, also known as benign intracranial hypertension or pseudotumour cerebri, is a condition of unknown aetiology characterised by raised ICP and papilloedema. IIH is found almost exclusively in obese women (90%), causing daily headaches and visual loss, which can be severe and permanent [1, 2] . Effective treatments are lacking and range from medical therapies to surgical procedures which offer symptomatic relief and prevent blindness [3] . The overall age-and gender-adjusted annual incidence is reported as 1.8 per 100,000, with an increase from 1.0 per 100,000 (1990-2001) to 2.4 per 100,000 (2002-2014; P = 0.007) [4] ; in line with the global obesity epidemic, the incidence of IIH is expected to rise [1] . The increasing economic burden of IIH has been highlighted by a number of groups [5, 6] .
Current therapy for IIH
The 2015 Cochrane review concluded there was insufficient evidence to determine which treatments are potentially beneficial in IIH [3] ; hence there is no clear guidance regarding standardised management.
Medical therapy can be used with the aim of lowering ICP. The Idiopathic Intracranial Hypertension Treatment Trial demonstrated acetazolamide has beneficial effects in patients with mild visual loss [7] . However, a pilot trial in the UK suggested many patients do not tolerate the drug well [8] . Topiramate has also been evaluated in IIH, but in the absence of a placebo arm it is difficult to interpret the results of this study [9] .
In cases of deteriorating vision, surgical techniques such as cerebrospinal fluid (CSF) diversion (shunting) or optic nerve sheath fenestration (ONSF) can be used to prevent blindness [10] . Shunting is generally not a satisfactory treatment, with a high revision rate [11] . There is significant morbidity from CSF shunting [11, 12] . The evidence for ONSF is mainly case based [13] , with reports of ongoing visual decline in a third of patients at 1 year and in nearly half at 3 years [14] . Patients waiting for a shunt and suffering disabling headaches with very high pressures may be offered repeated lumbar punctures (LP) to lower ICP, offering symptomatic relief.
Weight loss
We published a prospective study showing that a very low calorie diet leading to significant weight loss (15.3% ± 7.0% of body weight) significantly lowered ICP (8.0 ± 4.2 cmCSF, p<0.001) and significantly improved papilloedema, vision, and headache [15] . However, patients in our study later regained weight and their symptoms and signs of IIH returned, a documented phenomenon in the condition [16] .
Despite the recurrence of IIH following weight regain, our study demonstrates the efficacy of therapeutic weight loss. However, maintaining long term weight loss is difficult to achieve, with patients on average regaining one third to one half of lost weight at 12 months, and returning to original weight in 5 years [17, 18] . Sustainable approaches to weight loss are therefore likely to offer patients an effective treatment. Obesity pharmacological therapies such as orlistat are unlikely to achieve sufficient weight loss (typical reduction of 2.89kg [19] ) to significantly modify IIH.
Bariatric surgery for IIH
Bariatric surgery has many advantages as a potential treatment for IIH: 1) Weight loss is greater than other weight reducing approaches [20] . Hutter et al. give a mean reduction in BMI of 7.05-15.34 m/kg 2 at 12 months using the 3 procedures in use in this trial [21] ; 2) Weight loss is sustained [22] [23] [24] ; 3) Bariatric surgery is cost-effective compared to non-surgical interventions to manage obesity [25] ; 4) Bariatric surgery is safe: Mortality rates are typically 0.05-0.14%, similar to cholecystectomy or hysterectomy [21, 26, 27] . Major complications rates are 2-6% [21, [26] [27] [28] [29] [30] [31] [32] , similar to other common elective operations [26] .
NICE recommends bariatric surgery for people with a BMI over 40 kg/m 2 or in people with a BMI of over 35 kg/m 2 and a significant co-morbidity (e.g. type 2 diabetes) that may be improved with weight loss [33] . IIH is not one of the listed co-morbidities and IIH patients do not often have alternative co-morbidities that would qualify them for surgery.
There are no published systematic reviews or meta-analyses of weight modification or bariatric surgery in IIH, although an increasing number of case series and reports have been published describing its beneficial effects [34] . There is no long term data about sustained weight loss in IIH.
Rationale
The aim of this trial is to assess if sustained weight loss results in sustained reduction of ICP, visual symptoms and headaches, and which method, bariatric surgery or a dietary weight loss programme, is a viable method of achieving this. Bariatric surgery is an approach to sustainable significant weight loss, and so may offer long-term treatment of IIH. As it is not established how much weight loss is necessary to treat IIH, conservative weight management with dietary interventions may also offer long-term treatment.
Bariatric surgery is an invasive approach to weight reduction and a significant change from the current accepted treatment for IIH. To impact current clinical practice, we will compare bariatric surgery to an alternative weight loss regime (rather than current practice). The comparator arm will be a dietary weight loss programme using the internationally recognised Weight Watchers diet programme.
Weight Watchers is a widely available commercial weight loss programme, achieving superior weight loss and attendance compared to other commercially available (such as Slimming World or Rosemary Conley) or primary care led weight loss programmes [35] . Participants in Weight Watchers receive group support, access to online tools, and resources and advice on healthy eating. In one study, participants in Weight Watchers lost on average 4.4kg 3 months after joining the programme [35] .
Participants in the IIH:WT trial will be randomised between referral to bariatric surgery or to a dietary weight loss programme (Weight Watchers) for 12 months.
METHODS

Design
IIH:WT trial is a multi-centre randomised controlled parallel arm clinical trial of 64 participants with active IIH and a BMI over 35 kg/m 2 . Participants will be randomised in a 1:1 ratio to either bariatric surgery or a dietary weight loss programme and followed up for 5 years. Blinding The trial will necessarily be open label due to the nature of the intervention; assessors of visual outcomes will be masked to randomised treatment allocation. The primary outcome, ICP, is an objective measure.
Recruitment
Patients will be identified at Neurology and Ophthalmology clinics in UK NHS Trusts between July 2014 and October 2017.
The participant pathway through the trial is shown in Figure 1 . Apart from the trial treatments allocated at randomisation, other aspects of patient management are at the discretion of the local doctors.
Randomisation
Participants are randomised into the trial by telephone call to the Birmingham Clinical Trials Unit. A computer-generated randomisation list with allocation of treatment stratified by acetazolamide use will be used.
Treatment arms
Intervention arm • Participants randomised to surgery will be referred to bariatric surgery. If judged suitable according to the local screening processes, the participant will undergo Laparoscopic Adjustable Gastric Banding (LAGB), Roux-en-Y Gastric Bypass (RYGBP), or Laparoscopic Sleeve Gastrectomy (LSG). This will take approximately 4 months from randomisation to surgery. The choice of surgery will be made between surgeon and participant based upon the participant's health and preference, and standard NHS follow-up will be included.
Active control arm
• Participants randomised to the dietary weight loss programme will be given vouchers allowing access to weekly meetings at their local Weight Watchers group and Weight Watchers online and mobile tools for 12 months.
FOLLOW-UP AND OUTCOME MEASURES Primary Outcome Measure
• ICP at 12 months.
Secondary Outcome Measures
• ICP at 24 and 60 months.
• Reported IIH symptoms (pulsatile tinnitus, visual loss, diplopia, visual obscurations).
• Visual function (LogMAR chart to assess visual acuity, Humphrey Visual Fields 24-2, MARS charts to assess contrast sensitivity, Ishihara colour vision).
• Papilloedema (measured by spectral optical coherence tomography and fundus photography).
• Headache associated disability (headache diary, Headache Impact Test-6 score (HIT-6)).
• Anthropometric measures (BMI, waist/hip ratio, fat mass, blood pressure).
• Quality of life and wellbeing (EQ-5D-5L, ICECAP-A, SF-36, Hospital Anxiety and Depression score).
• Difference in number of referrals to CSF shunting and optic nerve sheath fenestration procedures between treatment arms.
• Change in Quality-Adjusted Life Years and/or Capability Wellbeing; offset against cost of treatment.
All outcomes will be measured at 12, 24 and 60 months.
Exploratory objectives
Participants with IIH and 20 matched obese control participants will give samples of blood and CSF. Some participants, including the 20 matched obese controls, will participate in sub-studies looking at the aetiology of IIH and the relationship between IIH and other obesity co-morbidities, from which they may suffer. These sub-studies will not be carried out at all sites and are not discussed in this paper. The control participants will undergo the same baseline assessment as randomised participants and then exit the study.
Format of assessment visits
When initially approached, participants will be asked to consent to a pre-screening assessment. This will consist of having their papilloedema assessed and graded according to the modified Frisén criteria. If papilloedema are present the participant will be asked to return for a screening visit. In the 7 days before the screening visit, the participant will complete a headache diary recording severity and frequency of headache, as well as analgesic use. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Participants will then have a screening assessment (0 months) which will be carried out according to Figure 2 and is described below.
Informed consent will first be taken and a urine pregnancy test carried out. Then the participant will undergo a series of visual assessments. If any of these assessments have been carried out in the 30 days prior to the screening visit as part of routine care then they will not be repeated, but the results taken from patient notes provided they have been performed as per trial protocol.
The visual assessments will be recorded in both eyes and these include:
• Best corrected visual acuity will be measured using LogMAR (log of the minimum angle of resolution) charts; • Best corrected contrast sensitivity will be measured using MARs charts;
• Colour vision will be assessed using the Ishihara pseudo-isochromatic plates;
• Automated perimetry with a Humphrey Visual Field (HVF) Analyzer using the SITA Standard 24-2 program. Where there is a high false positive rate the HVF will be repeated prior to LP; • Optical Coherence Tomography (Heidelberg Spectralis Spectral Domain OCT) will be acquired to record measurements including retinal nerve fibre layer. OCT scans will be sent for masked review by designated specialist readers; • Digital colour fundus photographs will be taken, centred on the optic disc with focus on the anterior surface of the swollen nerve head. These will be graded by masked reviewers.
After visual assessments are complete an LP will be performed. LP will be performed with the participant breathing steadily in the lateral position; legs extended greater than 90 o at the hip, with adequate time taken to ensure a stable reading. ICP will be recorded in cmCSF. Where required, LP will be performed with image guidance.
The LP will be carried out after all visual assessments as the LP temporarily lowers ICP and so potentially alters visual measurements. In all cases the LP will be done on the day of randomisation as ICP is the primary outcome.
Further assessment of headache will use the HIT-6 [38] , an assessment of the impact of headache over the previous month. Headache preventative use and use of acetazolamide/diuretics will be recorded.
The participant will complete quality of life questionnaires (QoL) following the LP. These include the generic health-related QoL questionnaires EQ-5D-5L (EuroQol five dimensions questionnaire), SF-36 Version 1 (RAND 36-Item Short Form Survey) and ICECAP-A (ICEpop CAPability measure for Adults), and the Hospital Anxiety and Depression score.
If the participant has ICP >25cmCSF, they will be randomised and the data collected at the prescreening and screening visits will be used for baseline data.
Participants will then be evaluated at 3, 6, 12, 24 and 60 months as shown in Table 1 . Participants randomised to surgery will also be evaluated at approximately 2 weeks post-surgery for an LP assessment of ICP. For this trial we hypothesise that the greater weight loss anticipated in the bariatric surgery arm compared to the dietary arm will consequently reduce the ICP further in the bariatric arm than in the dietary arm. A weight loss of 15.3% ± 7.0% of body weight over 3 months was achieved by patients following a low calorie diet [15] . Data from this study showed that ICP was significantly reduced by 20% (ICP at baseline in 20 IIH patients was 39.8 ± 5.1 cmCSF and ICP was reduced by 8 ± 4.2 cmCSF, p<0.001).
Assuming a conservative change of ICP in the bariatric surgery arm to that previously observed of 8cmCSF and a change of 3cmCSF in the dietary arm (to reflect changes slightly greater than the baseline fluctuations seen in our previous study), then we wish to detect a mean difference of 5cmCSF between the groups. To detect this difference of 5cmCSF with 90% power and alpha=0.05 using a 2-sided t-test (assuming a standard deviation of 5.1 [15] ) requires 46 patients (23 per arm). Allowing for a 25-28% drop out rate will require 32 patients per arm.
We believe that the SD of 5.1 is a true reflection of the variability of the data as this is taken from the baseline measurements from our previous study, in a similar population [15] . This assumption for the sample size calculation will be monitored during the trial. Projected accrual and attrition rates Recruitment for our previous study with very similar inclusion criteria was at a rate of 1.5 participants per month [15] ; we consequently feel that the recruitment target of 1.8 participants per month (64 participants over 3 years) is realistic and achievable. Attrition rates for this treatment and patient group is not known; we have allowed a 28% rate of drop out.
Statistical Analysis
The primary comparison groups will be composed of those randomised to the bariatric surgery arm and those randomised to the dietetic intervention arm. Analyses will be based on the intention to treat principle, i.e. all patients will be analysed in the treatment group to which they were randomised irrespective of compliance with the randomised allocated treatment or other protocol violation. Summary statistics and differences between groups (e.g. mean differences, relative risks) will be reported, with 95% confidence intervals and p-values from two-sided tests given. Outcomes will be adjusted for the stratification variable (acetazolamide use at entry). For all analyses, a p-value <0.05 will be considered statistically significant and there will be no adjustment for multiple testing.
Primary Outcome Analysis
The primary outcome will assess the ICP at 12 months. The ICP at 12 months for the two study arms will be compared using a linear regression model with baseline ICP and acetazolamide use at entry (stratification variable) included as covariates in the model.
Secondary Outcome Analyses
Secondary outcome measures include a mixture of continuous and categorical data items. Continuous outcomes (e.g. quality of life) will be analysed as per the primary outcome measure. Categorical outcomes (e.g. presence or absence of symptoms, number of CSF shunting referrals) will be expressed as the number and percentage of patients experiencing these outcomes in the two groups. Log-binomial models will be used to compare the data between the two study arms, with baseline data (where available, i.e. baseline symptom data) and acetazolamide use at entry (stratification variable) included in the model as covariates.
Health economic outcomes
The following analyses will assess the cost-effectiveness of bariatric surgery versus diet for IIH: 1.
Cost-effectiveness analysis -ICP measured at baseline and 12 months will be evaluated in terms of cost to reduce ICP by 12.5%.
2.
Cost-utility analysis -quality of life and wellbeing information from the EQ-5D-5L and ICECAP-A questionnaires at baseline and 12 months; cost-effectiveness will be expressed as 'cost per QALY gained' and 'cost per sufficient and full capability achieved'.
3.
Cost-benefit analysis -monetary outcomes will be elicited using the 'Willingness to Pay' method asked at baseline and at 12 months. Results will be expressed as a cost-benefit ratio and net-present value.
MONITORING
Safety reporting
There are no novel medical devices or Investigational Medicinal Products used as part of this trial. Any Serious Adverse Events (SAEs) will be reported on a trial-specific SAE form, evaluated by the Chief Investigator, and where required reported to sponsor and ethics committee. Independent Trial Steering Committee (TSC) A TSC will provide oversight of the study. The independent members are a consultant neurologist and neuro-ophthalmologist as chair, a consultant bariatric surgeon as independent expert, an independent statistician, and a patient representative.
Data Monitoring Committee (DMC)
A DMC will independently monitor the efficacy and safety data at least annually. The members are a consultant ophthalmologist as chair, a consultant bariatric surgeon as independent expert, and an independent statistician.
Compliance monitoring
Data on compliance in the bariatric surgery arm will be collected from local surgery teams. Compliance will be considered as undergoing bariatric surgery. Reasons for non-compliance will be recorded.
Data on attendance to Weight Watchers for participants in the dietary arm will be self-reported. It is not expected that participants will attend every session (30% of participants attended less than 50% of sessions over 12 weeks in one trial [35] and we expect a lower attendance rate over 12 months). The trial will be conducted according to the standards of the International Conference on Harmonisation-Good Clinical Practice (GCP) and the Research Governance Framework for Health and Social Care. Written informed consent will be provided by all patients prior to any trial-related procedures. Participants will be free to withdraw from the trial at any time without any effect on their standard of care.
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Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators -this is covered in the clinical trial site agreements between sites and sponsor Effective treatments are lacking and range from medical therapies to surgical procedures which offer symptomatic relief and prevent blindness. [3] The overall age-and gender-adjusted annual incidence is reported as 1.8 per 100,000, with an increase from 1.0 per 100,000 (1990-2001) to 2.4 per 100,000 (2002-2014; P = 0.007); [4] in line with the global obesity epidemic, the incidence of IIH is expected to rise. [1] The increasing economic burden of IIH has been highlighted by a number of groups. [5, 6] Current therapy for IIH The 2015 Cochrane review concluded there was insufficient evidence to determine which treatments are potentially beneficial in IIH; [3] hence there is no clear guidance regarding standardised management.
Medical therapy can be used with the aim of lowering ICP. The Idiopathic Intracranial Hypertension Treatment Trial demonstrated acetazolamide has beneficial effects in patients with mild visual loss. [7] However, a pilot trial in the UK suggested many patients do not tolerate the drug well. [8] Topiramate has also been evaluated in IIH, but in the absence of a placebo arm it is difficult to interpret the results of this study. [9] In cases of deteriorating vision, surgical techniques such as cerebrospinal fluid (CSF) diversion (shunting), optic nerve sheath fenestration (ONSF) or venous sinus stenting can be used to prevent blindness. [10] Shunting is generally not a satisfactory treatment, with a high revision rate. [11] There is significant morbidity from CSF shunting. [11, 12] The evidence for ONSF is mainly case based, [13] with reports of ongoing visual decline in a third of patients at 1 year and in nearly half at 3 years. [14] The evidence for venous sinus stenting is based on case series and retrospective studies, and long-term data is limited. [1, 2] Patients waiting for surgical intervention and suffering disabling headaches with very high pressures may be offered repeated lumbar punctures (LP) to lower ICP, offering symptomatic relief.
Weight loss
We published a prospective study showing that a very low calorie diet leading to significant weight loss (15.3% ± 7.0% of body weight) significantly lowered ICP (8.0 ± 4.2 cmCSF, p<0.001) and significantly improved papilloedema, vision, and headache. [15] However, patients in our study later regained weight and their symptoms and signs of IIH returned, a documented phenomenon in the condition. [16] Despite the recurrence of IIH following weight regain, our study demonstrates the efficacy of therapeutic weight loss. However, maintaining long term weight loss is difficult to achieve, with patients on average regaining one third to one half of lost weight at 12 months, and returning to original weight in 5 years. [17, 18] Sustainable approaches to weight loss are therefore likely to offer patients an effective treatment. Obesity pharmacological therapies such as orlistat are unlikely to achieve sufficient weight loss (typical reduction of 2.89kg) [19] There are no published systematic reviews or meta-analyses of weight modification or bariatric surgery in IIH, although an increasing number of case series and reports have been published describing its beneficial effects. [35] There is no long term data about sustained weight loss in IIH.
Rationale
The aim of this trial is to assess if sustained weight loss results in sustained reduction of ICP, visual symptoms and headaches, and which method, bariatric surgery or a dietary weight loss programme, is a viable method of achieving this.
Bariatric surgery is an approach to sustainable significant weight loss, and so may offer long-term treatment of IIH. Participants will receive a range of bariatric surgeries which will broadly reflect current practice in the NHS and will be chosen by participant and surgeon to best suit their preferences and any co-morbidities. This range of procedures has been chosen so that results will be as generalizable as possible to patients in the NHS rather than dependent on one procedure type. Different procedures result in different mean weight loss, but all 3 procedures in use in this trial should result in sufficient weight loss to be disease modifying according to our weight loss study. [15] Different metabolic effects from different procedures may additionally result in disease modification; this will be detected through the analysis of biomarkers from both blood and CSF samples and we will check for heterogeneity in outcomes between the 3 bariatric procedures included in the trial.
Bariatric surgery is an invasive approach to weight reduction and a significant change from the current accepted treatment for IIH. As it is not established how much weight loss is necessary to treat IIH, conservative weight management with dietary interventions may also offer long-term treatment. To impact current clinical practice, we will compare bariatric surgery to an alternative weight loss regime (rather than current practice). The comparator arm will be a dietary weight loss programme using the internationally recognised Weight Watchers diet programme.
Weight Watchers is a widely available commercial weight loss programme, achieving superior weight loss and attendance compared to other commercially available (such as Slimming World or Rosemary Conley) or primary care-led weight loss programmes. [36] Participants in Weight Watchers receive group support, access to online tools, and resources and advice on healthy eating. In one study, participants in Weight Watchers lost on average 4.4kg 3 months after joining the programme. [36] Participants in the IIH:WT trial will be randomised between referral to bariatric surgery or to a dietary weight loss programme (Weight Watchers) for 12 months.
METHODS Design
IIH:WT trial is a multi-centre randomised controlled parallel arm clinical trial of 64 participants with active IIH and a BMI over 35 kg/m 2 . Participants will be randomised in a 1:1 ratio to either bariatric surgery or a dietary weight loss programme and followed up for 5 years.
Blinding
The trial will necessarily be open label due to the nature of the intervention; assessors of visual outcomes will be masked to randomised treatment allocation. The primary outcome, ICP, is an objective measure. 3. Significant co-morbidity, Cushing's syndrome, Addison's disease or the use of oral or injected steroid therapy. 4. Undergone optic nerve sheath fenestration. 5. Definite indication for or contraindication against surgery or dieting. 6. Have a specific medical or psychiatric contraindication for surgery, including drug misuse, eating disorder or major depression (suicidal ideation, drug overdose or psychological admission in last 12 months). 7. Previous bariatric surgery. 8. Inability to give informed consent e.g. due to cognitive impairment.
Recruitment
Apart from the trial treatments allocated at randomisation, other aspects of patient management (e.g. use of acetazolamide or topiramate) are at the discretion of the local doctors.
Randomisation
Participants are randomised into the trial by telephone call to the Birmingham Clinical Trials Unit. A computer-generated randomisation list with allocation of treatment stratified by acetazolamide use will be used. Stratification will not be according to topirimate as well as acetazolamide use due to the low number of participants.
Treatment arms Intervention arm
• Participants randomised to surgery will be referred to bariatric surgery. If judged suitable according to the local screening processes, the participant will undergo Laparoscopic Adjustable Gastric Banding (LAGB), Roux-en-Y Gastric Bypass (RYGBP), or Laparoscopic Sleeve Gastrectomy (LSG). This will take approximately 4 months from randomisation to surgery. The choice of surgery will be made between surgeon and participant based upon the participant's health and preference, and standard NHS follow-up will be included.
Active control arm
FOLLOW-UP AND OUTCOME MEASURES Primary Outcome Measure
Secondary Outcome Measures
• Quality of life and wellbeing (EQ-5D-5L, ICECAP-A, SF-36, Hospital Anxiety and Depression score). • Difference in number of referrals to CSF shunting and optic nerve sheath fenestration procedures between treatment arms.
Exploratory objectives
Participants with IIH and 20 matched obese control participants will give samples of blood (36mls) and CSF (10mls) at baseline and 12, 24 and 60 months for fasting metabolic evaluation, evaluation of polycystic ovary syndrome status, and exploratory analysis including biomarkers such as fasting insulin.
Some participants, including the 20 matched obese controls, will participate in sub-studies looking at the aetiology of IIH and the relationship between IIH and other obesity co-morbidities, from which they may suffer. The sub-studies include a sleep apnoea observational sub-study, a cognitive function sub-study, a magnetic resonance imaging sub-study, and a metabolic syndrome sub-study. Patients will be assessed at baseline (to evaluate the presence of co-morbidities in our patient population and for comparison to the matched obese control patients) and at 12 months (to evaluate possible changes due to weight loss). These sub-studies will not be carried out at all sites and are not discussed in further detail in this paper. The control participants will undergo the same baseline assessment as randomised participants and then exit the study.
Format of assessment visits
When initially approached, participants will be asked to consent to a pre-screening assessment. This will consist of having their papilloedema assessed and graded according to the modified Frisén criteria. If papilloedema are present the participant will be asked to return for a screening visit. In the 7 days before the screening visit, the participant will complete a headache diary recording severity and frequency of headache, as well as analgesic use.
Participants will then have a screening assessment (0 months) which will be carried out according to Figure 2 and is described below.
After visual assessments are complete an LP will be performed. LP will be performed with the participant breathing steadily in the lateral position; legs flexed 90 o at the hip, with adequate time taken to ensure a stable reading. ICP will be recorded in cmCSF. Where required, LP will be performed with image guidance.
Further assessment of headache will use the HIT-6, [39] an assessment of the impact of headache over the previous month. Headache preventative use (e.g. topirimate) and use of acetazolamide/diuretics will be recorded.
Participants will then be evaluated at 3, 6, 12, 24 and 60 months as shown in Table 1 . Participants randomised to surgery will also be evaluated at approximately 2 weeks post-surgery for an LP assessment of ICP. 
ANALYSIS
Sample size Total n=64. 32 participants in each arm (bariatric surgery versus dietary weight loss programme).
For this trial we hypothesise that the greater weight loss anticipated in the bariatric surgery arm compared to the dietary arm will consequently reduce the ICP further in the bariatric arm than in the dietary arm. A weight loss of 15.3% ± 7.0% of body weight over 3 months was achieved by patients following a low calorie diet. [15] Data from this study showed that ICP was significantly reduced by 20% (ICP at baseline in 20 IIH patients was 39.8 ± 5.1 cmCSF and ICP was reduced by 8 ± 4.2 cmCSF, p<0.001).
Assuming a conservative change of ICP in the bariatric surgery arm to that previously observed of 8cmCSF and a change of 3cmCSF in the dietary arm (to reflect changes slightly greater than the baseline fluctuations seen in our previous study), then we wish to detect a mean difference of 5cmCSF between the groups. To detect this difference of 5cmCSF with 90% power and alpha=0.05 using a 2-sided t-test (assuming a standard deviation of 5.1) [15] requires 46 patients (23 per arm). Allowing for a 28% drop out rate will require 32 patients per arm.
We believe that the SD of 5.1 is a true reflection of the variability of the data as this is taken from the baseline measurements from our previous study, in a similar population. [15] This assumption for the sample size calculation will be monitored during the trial.
Projected accrual and attrition rates
Recruitment for our previous study with very similar inclusion criteria was at a rate of 1.5 participants per month; [15] we consequently feel that the recruitment target of 1.4 participants per month (64 participants over 45 months) is realistic and achievable. Attrition rates for this treatment and patient group is not known; we have allowed a 28% rate of drop out. Attrition will be monitored by the Trial Management Group and by the oversight committees and we will attempt to improve participant engagement through participant newsletters, participant compensation, patient support days, and engagement with the IIH UK patient charity.
Statistical Analysis
The primary comparison groups will be composed of those randomised to the bariatric surgery arm and those randomised to the dietary weight loss arm. Analyses will be based on the intention to treat principle, i.e. all patients will be analysed in the treatment group to which they were randomised irrespective of compliance with the randomised allocated treatment or other protocol violations. Summary statistics and differences between groups (e.g. mean differences, relative risks) will be reported, with 95% confidence intervals and p-values from two-sided tests given.
Outcomes will be adjusted for the stratification variable (acetazolamide use at entry). For all analyses, a p-value <0.05 will be considered statistically significant and there will be no adjustment for multiple testing. 
Primary Outcome Analysis
Secondary Outcome Analyses
Health economic outcomes
2.
3.
MONITORING
Safety reporting
There are no novel medical devices or Investigational Medicinal Products used as part of this trial. Any Serious Adverse Events (SAEs) including surgical mortality and complications will be reported on a trial-specific SAE form, evaluated by the Chief Investigator, and where required reported to sponsor and ethics committee.
Independent Trial Steering Committee (TSC)
A TSC will provide oversight of the study. The independent members are a consultant neurologist and neuro-ophthalmologist as chair, a consultant bariatric surgeon as independent expert, an independent statistician, and a patient representative.
Data Monitoring Committee (DMC)
Compliance monitoring
Data on attendance to Weight Watchers for participants in the dietary arm will be self-reported and given in terms of percentage of sessions attended. It is not expected that participants will 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 attend every session (30% of participants attended less than 50% of sessions over 12 weeks in one trial [36] and we expect a lower attendance rate over 12 months). The trial will be conducted according to the standards of the International Conference on Harmonisation-Good Clinical Practice (GCP) and the Research Governance Framework for Health and Social Care. Written informed consent will be provided by all patients prior to any trial-related procedures. Participants will be free to withdraw from the trial at any time without any effect on their standard of care.
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